BioInfra
At a glance
BioInfra filed 30 disclosures in the last 12 months, including 2 insider, 1 earnings and 1 m&a. The most recent key filing was on Oct 12: President bought 10,500 sh on the market, Oct 8–12.
The 2025 annual report lists 141 employees with an average tenure of 3.3 years and average pay of ₩47.8M, #1549 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩402.4M each on average. It paid ₩300 per common share in cash dividends, against ₩400 a year earlier (-25%). 이상득 and related parties held 42.45% at year end.
From the 2025 annual report
Staff: 141 (44 men, 97 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩8.3B. Directors and auditors: 6, paid ₩614.5M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩300 | ₩400 | ₩600 |
| Payout ratio | -16% | -48.9% | 143.8% |
| Yield (as filed) | 6.22% | 5.92% | 5.27% |
| Total cash dividends | ₩1.5B | ₩1.9B | ₩2.9B |
Largest shareholder
이상득 holds 42.45%; with 0 related parties the group holds 42.45% of common shares at year end.
Auditor: 서현회계법인 · opinion: Unqualified.
Rankings: Dividend yield #66 of 1,084
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.